Tenapanor is an NHE3 inhibitor indicated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic kidney disease,. Tenapanor is a novel, small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C).
- Mechanism
- Curator reviewed · 4 references
Tenapanor is a locally-acting small molecule inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3), an antiporter expressed on the apical surface of enterocytes in the small intestine and colon which is involved in sodium-fluid homeostasis. By inhibiting this antiporter tenapanor causes retention of sodium within the lumen of the intestine - this results in an osmotic gradient that draws water into the lumen and softens stool consistency.
There is some evidence that tenapanor can inhibit the uptake of dietary phosphorus in the gastrointestinal tract, though the exact mechanism of this activity has yet to be elucidated.
- Primary indication
- Tenapanor is indicated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) in adults.Curator reviewed · 2 structured indications
- Formula / weight
- C50H66Cl4N8O10S2 · 1145.04 g/mol (avg)
- First approval
- Canada, 2020 · United States, 2019
- Code names
- AZD-1722
- Brand names
Resolves to
DNHPDWGIXIMXSA-CXNSMIOJSA-NSMILESCN1C[C@@H](C2=CC(=CC=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C2=CC(=CC=C2)[C@@H]2CN(C)CC3=C2C=C(Cl)C=C3Cl)C2=C(C1)C(Cl)=CC(Cl)=C2What you can answer from here — as of September 16, 2026
Which drugs share a target with Tenapanor, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account